Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients? - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Expert Review of Clinical Immunology Année : 2014

Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?

Résumé

Thiopurines remain the backbone therapy of inflammatory bowel diseases (IBD). However, these drugs have potential mutagenic and carcinogenic effects, especially when prescribed for a long time. In addition to the increased risk of lymphoma and non-melanoma skin cancer, recent data suggest that risk of myeloid disorder is increased in IBD patients with past exposure to thiopurines. Even if individual risk is low, practitioners who take care of IBD patients should be aware of this potential complication of thiopurines treatment.
Fichier non déposé

Dates et versions

hal-01699614 , version 1 (02-02-2018)

Identifiants

Citer

Anthony Lopez, Laurent Beaugerie, Laurent Peyrin-Biroulet. Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?. Expert Review of Clinical Immunology, 2014, 10 (12), pp.1563 - 1565. ⟨10.1586/1744666X.2014.977261⟩. ⟨hal-01699614⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More